XNCR - Xencor, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
39.08
+0.52 (+1.35%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close38.56
Open38.77
Bid0.00 x 800
Ask0.00 x 1300
Day's Range37.95 - 39.17
52 Week Range27.75 - 48.38
Volume511,757
Avg. Volume233,656
Market Cap2.202B
Beta (3Y Monthly)0.73
PE Ratio (TTM)56.64
EPS (TTM)0.69
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est43.64
Trade prices are not sourced from all markets
  • Company News For Jun 26, 2019
    Zacks21 hours ago

    Company News For Jun 26, 2019

    Companies in the news are: ABBV, AGN, LEN, XNCR, USNA and LION

  • PR Newswire3 days ago

    MarketAxess Holdings Set to Join S&P 500; Axon Enterprise to Join S&P MidCap 400; Others to Join S&P SmallCap 600

    NEW YORK , June 24, 2019 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400 and S&P SmallCap 600:   S&P MidCap 400 constituent MarketAxess Holdings Inc. ...

  • Here’s What Hedge Funds Think About Xencor Inc (XNCR)
    Insider Monkey3 days ago

    Here’s What Hedge Funds Think About Xencor Inc (XNCR)

    Amid an overall bull market, many stocks that smart money investors were collectively bullish on surged during the first quarter. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 40% and 25% respectively. Our research shows that most of the stocks that smart money likes historically generate strong risk-adjusted […]

  • Markit9 days ago

    See what the IHS Markit Score report has to say about Xencor Inc.

    Xencor Inc NASDAQ NMS:XNCRView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate and increasing * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NeutralShort interest is moderate for XNCR with between 5 and 10% of shares outstanding currently on loan. This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on June 7. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding XNCR are favorable, with net inflows of $2.59 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • One Thing To Remember About The Xencor, Inc. (NASDAQ:XNCR) Share Price
    Simply Wall St.19 days ago

    One Thing To Remember About The Xencor, Inc. (NASDAQ:XNCR) Share Price

    Anyone researching Xencor, Inc. (NASDAQ:XNCR) might want to consider the historical volatility of the share price...

  • Business Wire24 days ago

    Xencor Doses First Patient in Phase 1 Study of XmAb®22841 for the Treatment of Patients with Advanced Solid Tumors

    Xencor, Inc. (XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases, today announced that the first patient has been dosed in a Phase 1 clinical study to evaluate the safety and tolerability of XmAb22841, both as a monotherapy and in combination with pembrolizumab, in patients with advanced solid tumors. XmAb22841 is a bispecific antibody that simultaneously targets the immune checkpoint receptors CTLA-4 and LAG-3.

  • Business Wirelast month

    Xencor Appoints Jeremy Grunstein, Ph.D., as Vice President, Business Development

    Xencor, Inc. (XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases, today announced the appointment of Jeremy Grunstein, Ph.D., as vice president, business development. Dr. Grunstein brings more than 15 years of expertise in partnering, acquisitions and licensing in the biopharmaceutical industry and will lead strategic partnering to enhance the development of Xencor’s pipeline of drug candidates.

  • Thomson Reuters StreetEventslast month

    Edited Transcript of XNCR earnings conference call or presentation 9-May-19 8:30pm GMT

    Q1 2019 Xencor Inc Earnings Call

  • Xencor Inc (XNCR) Q1 2019 Earnings Call Transcript
    Motley Fool2 months ago

    Xencor Inc (XNCR) Q1 2019 Earnings Call Transcript

    XNCR earnings call for the period ending March 31, 2019.

  • Associated Press2 months ago

    Xencor: 1Q Earnings Snapshot

    On a per-share basis, the Monrovia, California-based company said it had profit of $1.38. The results surpassed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...

  • Business Wire2 months ago

    Xencor Reports First Quarter 2019 Financial Results

    -- Management to Host Conference Call at 4:30 p.m. ET today --

  • Business Wire2 months ago

    Xencor to Present at Upcoming Investor Conferences

    Xencor, Inc.  , a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune disease, asthma and alle

  • Business Wire2 months ago

    Xencor Doses First Patient in Phase 1 Study of XmAb®23104 for the Treatment of Patients with Advanced Solid Tumors

    Xencor, Inc. (XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases, today announced that the first patient has been dosed in XmAb23104-01 (DUET-3), a Phase 1 clinical study to evaluate the safety and tolerability of XmAb23104, a bispecific antibody that simultaneously targets the immune receptors PD-1 and ICOS, for the treatment of patients with advanced solid tumors.

  • Business Wire2 months ago

    Xencor to Host First Quarter 2019 Financial Results Webcast and Conference Call on May 9, 2019

    Xencor, Inc.  , a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases, today announced that it will release first quarter 2019 financial results after the market closes on Thursday, May 9, 2019.

  • Is Xencor, Inc. (NASDAQ:XNCR) Trading At A 24% Discount?
    Simply Wall St.2 months ago

    Is Xencor, Inc. (NASDAQ:XNCR) Trading At A 24% Discount?

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! In this article we are going to estimate the intrinsic value of Xencor, Inc. (NASDAQ:XNCR) by ta...

  • Business Wire2 months ago

    Xencor Announces Partial Clinical Hold Lifted on Phase 1 Study of XmAb®14045

    Xencor, Inc. (XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases, today announced the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold that was placed on the Phase 1 study of XmAb14045, a CD123 x CD3 bispecific antibody molecule being evaluated in patients with relapsed or refractory acute myeloid leukemia and other CD123-expressing hematologic malignancies. “We are working with investigational sites to resume enrollment based on the amended protocol, through which we have sought to enhance the safety of patients participating in the study,” said Paul Foster, M.D., senior vice president and chief medical officer at Xencor.

  • Business Wire3 months ago

    Xencor and Astellas Enter Collaboration for Novel Bispecific Antibody Program

    Xencor, Inc. (XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune disease, asthma and allergic diseases, today announced it has entered into a research and license agreement in which Astellas Pharma Inc. will access Xencor’s bispecific technology to advance a novel bispecific antibody program in oncology. Xencor and Astellas will collaborate to generate bispecific antibodies directed toward a selected anti-tumor target for the potential treatment of patients with cancer, and Astellas will have an exclusive worldwide license to develop and commercialize novel drug candidates.

  • Business Wire3 months ago

    Xencor to Participate in Upcoming Investor Conferences

    Xencor, Inc.  , a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune disease, asthma and alle